Equities research analysts predict that TG Therapeutics Inc (NASDAQ:TGTX) will report $40,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for TG Therapeutics’ earnings. TG Therapeutics also reported sales of $40,000.00 in the same quarter last year. The company is expected to issue its next quarterly earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that TG Therapeutics will report full year sales of $170,000.00 for the current fiscal year, with estimates ranging from $150,000.00 to $200,000.00. For the next financial year, analysts expect that the firm will report sales of $170,000.00, with estimates ranging from $150,000.00 to $200,000.00. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.04). TG Therapeutics had a negative net margin of 97,412.51% and a negative return on equity of 177.79%. The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million.
TGTX stock traded down $0.14 during midday trading on Friday, reaching $5.28. 46,067 shares of the company’s stock traded hands, compared to its average volume of 1,372,790. TG Therapeutics has a 52-week low of $4.95 and a 52-week high of $17.35. The stock has a market cap of $463.78 million, a P/E ratio of -2.80 and a beta of 1.35.
Several hedge funds and other institutional investors have recently made changes to their positions in TGTX. venBio Select Advisor LLC increased its stake in shares of TG Therapeutics by 58.7% in the first quarter. venBio Select Advisor LLC now owns 5,229,619 shares of the biopharmaceutical company’s stock worth $74,261,000 after purchasing an additional 1,935,156 shares in the last quarter. RA Capital Management LLC increased its stake in shares of TG Therapeutics by 73.1% in the second quarter. RA Capital Management LLC now owns 4,278,796 shares of the biopharmaceutical company’s stock worth $56,266,000 after purchasing an additional 1,806,452 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of TG Therapeutics by 2,148.1% in the second quarter. Wells Fargo & Company MN now owns 888,768 shares of the biopharmaceutical company’s stock worth $11,686,000 after purchasing an additional 849,233 shares in the last quarter. BlackRock Inc. increased its stake in shares of TG Therapeutics by 17.4% in the second quarter. BlackRock Inc. now owns 4,081,050 shares of the biopharmaceutical company’s stock worth $53,667,000 after purchasing an additional 605,844 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of TG Therapeutics in the first quarter worth $8,574,000. 48.99% of the stock is owned by hedge funds and other institutional investors.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Further Reading: What is the Ex-Dividend Date in Investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.